Biological significance of serum soluble tumor necrosis factor receptor I in hepatoma patients

Table 3 Mean serum levels of sTNF-RI in 25 hepatoma patients before and after chemotherapy and their relationship to clinical response

Patient no.	Stage	Chemotherapy	Clinical response	sTNF-RI
				Before	After
1	IV	A	PR	3.25	3.07
2	IV	A	PR	3.38	3.11
3	IV	A	PR	3.15	2.83
4	IV	V	D	2.95	3.36
5	III	A	D	2.33	2.91
6	III	A	D	2.97	3.38
7	IV	A	PR	2.65	2.37
8	III	A	D	2.36	2.84
9	III	A	D	2.38	2.74
10	IV	A	D	2.79	3.16
11	III	A	PR	2.62	2.53
12	IV	A	D	3.18	3.46
13	IV	A	D	3.07	3.23
14	IV	A	D	3.52	3.93
15	IV	V	D	3.44	3.51
16	IV	A	D	3.27	3.67
17	IV	A	PR	2.96	2.73
18	III	A	CR	2.78	2.11
19	III	A	PR	2.74	2.53
20	IV	A	CR	3.25	2.87
21	IV	V	D	2.79	3.43
22	IV	V	D	3.54	4.18
23	III	V	D	2.62	3.11
24	IV	V	D	2.88	3.22
25	IV	V	D	3.85	4.63
	x-± s	Patients in remission (n = 9)		2.98 ± 0.29	2.67 ± 0.34
		Patients showing deterioration (n = 16)		2.99 ± 0.53	3.39 ± 0.43

A: FAPM transcatheter arterial chemoembolization with 5-Fu 1 g, ADM 50 mg, CDDP 100 mg, MMC 10 mg; V: FAM chemotherapy via peripheral vein with 5-Fu 500 mg, ADM 40 mg, MMC 8 mg.

CR: Complete remission; PR: Partial remission; D: Deterioration.